Cell Science Systems CEO to Present at Transforming Healthcare Conference


Roger Deutsch, CEO of Cell Science Systems, Corp (CSS) headquartered in Deerfield Beach, Florida, will speak at the upcoming Navigating Healthcare Transformation: Value Based Care, The Patient and the Technology, a Frost and Sullivan Medical Technologies, EXECUTIVE MINDXCHANGE event in San Diego, March 4-7. CSS was granted the Company of the Year award by Frost and Sullivan in 2016 for Food Intolerance testing, North America.



The conference is especially relevant in light of yesterday’s announcement from Amazon, JP Morgan Chase, and Berkshire Hathaway, regarding the formation of a new joint health care company to rein in high costs of healthcare for their over one million employees. According to Warren Buffett, Berkshire Chairman and CEO, “The ballooning costs of health care act as a hungry tapeworm on the American economy.” Healthcare costs in the US rose to $3.3 trillion in 2016; or 18% of the country’s GDP.


Deutsch will join a panel of top executives presenting at the Disruptive Innovators, Spotlight on Companies in Action program that offers health care industry leaders the opportunity to hear directly from entrepreneurs about new products and services that have the potential to transform healthcare.


“This is a good venue to inform insurance companies and others that the latest generation Alcat Test, a simple and relatively inexpensive lab-based blood test for detecting patients’ food and chemical sensitivities can substantially reduce excessive cost burden,” says Deutsch. “With healthcare costs skyrocketing, obesity levels, metabolic disorders, auto-inflammatory and auto-immune diseases increasing, accurate identification of triggers of inflammation represents a valuable tool that can complement any form of therapy,” he adds.


Epidemiologists estimate that 70% of degenerative diseases can be prevented by lifestyle and diet. The need is great and the marketplace for personalized eating advisors and technologies has recently seen many new entrants. These include genetic tests, as well as antibody assays. However, neither of these technologies has been validated by rigorous study at a major institution. Hence, the medical establishment has been reluctant to adopt them. However, the Alcat Test now has been validated through the gold standard method of a randomized controlled trial in research conducted at Yale School of Medicine and reported in the September 20, issue of BMJ Open Gastroenterology, which has been the most read article in that journal since its publication.


Genetic tests hold much fascination but are currently unable to pinpoint inflammation promoting foods and their recommendations are general. This is because of epigenetics. Any particular gene may be expressed or silenced by virtue of epigenetic modification which explains why even identical twins, who have identical genomes, do not have identical health histories. “Without the knowledge of epigenetic modifiers, knowing of a genetic predisposition is like reading the first three pages of Tolstoy’s War and Peace and believing you have the whole story,” says Deutsch. Epigenetics is an active area of research but new diagnostics have not yet been developed.


Likewise, IgG antibody tests are aggressively promoted by many small labs, and also through mail order, as a way to identify food sensitivities. However, IgG antibodies only show normal responses to food exposure and do not signal that a pathological process like chronic sterile inflammation is occurring. Even people without symptoms have them.


The Alcat Test, by contrast, is a cellular response test or leucocyte activation test developed by Cell Science Systems,  that directly reflects how the immune system cells respond to a particular food or other categories of substances; such as, additives/colorings, medicinal herbs, commonly used drugs and others.


“This has two advantages,” says Deutsch. “Firstly, it’s the cells that produce the inflammatory mediators and free radicals which, in the absence of any real threat, cause chronic activation of the innate immune system. Scientists have known for years that this phenomenon, also referred to as “silent inflammation”, underlies metabolic syndrome and other inflammatory diseases. Secondly, the activation of the white blood cells has been shown to correlate with eating the food in real life, as confirmed in studies using double blinded oral challenges and placebo controls.”


The Yale researchers used the Alcat Test to construct individualized therapeutic diets for patients suffering from irritable bowel syndrome or IBS. Subjects’ symptom scores were compared to those of a control group following a placebo diet in a double-blinded randomized control trial. Those following the Alcat diet experienced much greater reduction of symptoms.


Professor Joseph A. Bellanti, who teaches immunology and microbiology at Georgetown University, states, “I think it’s time that we look more carefully at the role of the innate immune system as the causative factor in many diseases.”



Cell Science Systems, Corporation (CSS) developer and provider of the Alcat test, and recipient of the Company of the Year Award, Food Intolerance Testing -N. America (Frost & Sullivan) is the market leader in food intolerance testing. The Alcat Test is a cellular test that accurately and conveniently detects, in patients’ blood, pathological responses to ordinary substances; including, foods, chemicals, molds, functional foods, additives and drugs. Application of test results has shown benefit to various otherwise complicated, non-resolving health issues; such as, IBS, Crohn’s, skin, respiratory, metabolic, neurologic, joint, fatigue issues and numerous others. The Alcat test stands alone as the only test of its kind to have been independently validated in university studies.




Cell Science Systems, Corp

Jason Deutsch




View source version on businesswire.com: http://www.businesswire.com/news/home/20180131006304/en/